COMPASS Pathways plc: Business Overview, Financials & Competitive Analysis
COMPASS Pathways plc scores 8/10 on the AskCyborg Cyborg Score (Strong). Breakthrough clinical data combined with strong capital position creates compelling risk-reward for a first-in-class mental health therapeutic. The company achieved a major clinical milestone with its Phase 3 trial meeting primary endpoints with high significance, positioning COMP360 as a potential first-in-class therapy for treatment-resistant depression with FDA filing underway.
What is COMPASS Pathways plc's industry? COMPASS Pathways plc (compasspathways.com) operates in Biotechnology / Psychedelic-Assisted Mental Health Therapeutics. AskCyborg classifies COMPASS Pathways plc under Biotechnology / Psychedelic-Assisted Mental Health Therapeutics in its company registry.
COMPASS Pathways is a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, pioneering a new paradigm for treating mental health conditions through the developme...
Cyborg Score thesis
Breakthrough clinical data combined with strong capital position creates compelling risk-reward for a first-in-class mental...
Read the full analyst-debate transcript →Get the Latest COMPASS Pathways plc Report
Up-to-date AI-powered research, analyst debate audio & saved-company playlists
Get Current Report FreeCOMPASS Pathways plc Overview
Pro stress-test →COMPASS Pathways is a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, pioneering a new paradigm for treating mental health conditions through the development of its investigational COMP360 synthetic psilocybin treatment, a potential first-in-class therapy. The company's pivotal Phase 3 trial of COMP360 for treatment-resistant depression met its primary endpoint with high statistical significance in February 2026.
Strategic Profile
Pro stress-test →COMP360 has Breakthrough Therapy designation from the FDA and has received Innovative Licensing and Access Pathway (ILAP) designation in the UK for treatment-resistant depression. Recent capital raises of $150 million and $200 million from warrant exercises will fund Phase 3 COMP360 trials, PTSD studies, and commercial preparation efforts, with cash runway extended into 2028.
Competitive Landscape
Pro stress-test →COMPASS Pathways competes in the emerging psychedelic therapeutics market targeting patients with serious mental health conditions not helped by existing treatments, positioning COMP360 as a potential first-in-class synthetic psilocybin solution. Key competitors include other psychedelic-assisted therapy developers such as Atai Life Sciences-backed companies and traditional depression treatment makers (SSRIs, ketamine clinics).
Industry Context
COMPASS Pathways plc operates in Biotechnology / Psychedelic-Assisted Mental Health Therapeutics.
Key facts
Founded: 2016 · Headquarters: London, United Kingdom